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Introduction: Substance P (SP) is a member of the tachykinin family of neuropeptides, which are widely distributed
throughout the central nervous system (CNS) and actively involved in inflammatory processes. SP is released early
following acute injury to the CNS, promoting a neurogenic inflammatory response characterized by an increase in
the permeability of the blood–brain barrier and the development of vasogenic edema. High levels of SP could lead
to an exacerbated inflammatory response that could be fatal for patients with traumatic brain injury (TBI). Thus, the
main goal of the present study was to determine whether serum SP levels are associated with injury severity and
mortality in patients with severe TBI.
Methods: This multicenter, observational, prospective study was carried out in six Spanish intensive care units and
included patients with Glasgow Coma Scale (GCS) scores ≤8. Patients with an Injury Severity Score ≥10 in non-cranial
aspects were excluded. Blood samples were collected on day 1 of TBI to measure serum SP levels. The endpoint was
30-day mortality.
Results: We found higher serum SP levels (P =0.002) in non-surviving patients (n =27) than in surviving patients (n =73).
The area under the curve for serum SP levels with regard to predicting 30-day mortality was 0.70 (95% confidence interval
(CI), 0.60 to 0.79; P <0.001). Survival analysis showed that patients with serum SP levels >299 pg/ml had higher 30-day
mortality than patients with lower levels (hazard ratio =3.7; 95% CI, 1.75 to 7.94; P <0.001). Multiple binomial logistic
regression analysis showed that serum SP levels >299 pg/ml were associated with 30-day mortality when we controlled
for APACHE II score and Marshall computed tomography lesion classification (odds ratio (OR) =5.97; 95% CI, 1.432 to
24.851; P =0.01) and for GCS score and age (OR =5.71; 95% CI, 1.461 to 22.280; P =0.01). We found a negative association
between serum SP levels and GCS score (Spearman’s ρ = −0.22; P =0.03).
Conclusions: We report, for the first time to our knowledge, that serum SP levels were associated with injury severity and
mortality in patients with severe TBI. These results open the possibility that SP antagonists may be useful in the treatment
of patients with severe TBI.Introduction
Traumatic brain injury (TBI) is a leading cause of death,
disability and resource consumption [1]. There are two
kinds of brain injury in TBI: primary and secondary in-
juries. Primary injury refers to the initial physical forces
applied to the brain at the moment of impact and leads
to shearing, laceration and stretching of nerve fibers* Correspondence: lorentemartin@msn.com
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unless otherwise stated.[2,3]. Secondary injury is a term applied to the destruc-
tive and self-propagating biological changes in cells and
tissues that lead to their dysfunction or death during the
hours to weeks after the initial insult [4]. One of the
process that contribute to these biological changes is
neurogenic inflammation, characterized by the release of
substances from primary sensory nerves, leading to vaso-
dilation, protein extravasation and tissue swelling [5,6].
Substance P (SP), calcitonin gene-related peptide and
neurokinin A are neuropeptides present in the sensory C
fibers that densely surround cerebral blood vessels [7,8].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ciated with increased microvascular permeability and
edema formation [9-11]. It is widely accepted that the
development of edema has adverse consequences in TBI
outcome through effects on intracranial pressure [12].
Apart from neurogenic inflammation, SP is also involved
in the classical inflammatory response mediated by activa-
tion of its preferred neurokinin 1 receptor (NK1R), which is
widely distributed throughout the central nervous system
(CNS) [13]. Brain injury increases NK1R expression in
neurons and astrocytes [14], and SP, acting through this
receptor, leads to astrocyte activation. Reactive astrocytes
proliferate and produce several soluble proinflammatory
mediators, such as cytokines, prostaglandins and thromb-
oxane derivatives [14-17]. In addition, both SP and NK1R
are expressed in microglial cells, which are involved in initi-
ation and/or progression of immune responses within the
CNS [17]. Microglia respond to traumatic injury by migrat-
ing to the site of challenge, where they assume many of the
immune effector functions typically associated with macro-
phages [17]. Stimulation of microglia by SP initiates activa-
tion of nuclear factor κB (NF-κB), a transcriptional activator
involved in expression of proinflammatory cytokines [18]. In
fact, microglia produce interleukin (IL)-1 in response to SP
[19]. Apart from microglia, other brain cells can be activated
by SP. In this sense, it has been shown that SP interacts with
NK1R receptors present on the human neuronal cell line
NT2N, inducing the expression of the potent chemokine
macrophage inflammatory protein 1 [20]. In addition, SP
can activate the transcription factors NF-κB and p38
mitogen-activated protein kinase in astrocyte cell lines, lead-
ing to the production of the proinflammatory cytokines IL-
1, IL-6 and IL-8 [21-23]. Finally, SP can promote leukocyte
chemotaxis through NK1R expressed in many inflammatory
and immune cells, leading to the extravasation, migration
and subsequent accumulation of leukocytes at sites of injury
[5,24]. Infiltrating immune cells can contribute to the pro-
duction of proinflammatory signals [25-28].
All these data suggest that SP is actively involved in
the inflammatory processes following brain injury. Al-
though SP increases after damage can be beneficial in
fighting host infections associated with TBI [29], it may
also play an important role in exacerbating inflammatory
immune responses in the CNS, which may be fatal for
patients with TBI. We therefore framed our hypothesis
by testing whether serum SP levels were associated with
injury severity and mortality in patients with severe TBI
and whether these levels would be clinically useful in
predicting mortality in these patients.
Material and methods
Design and subjects
This was a multicenter, observational, prospective study
carried out in six intensive care units in Spain between2009 and 2012. We included patients with severe TBI, de-
fined as Glasgow Coma Scale (GCS) [30] score ≤8 points.
We excluded individuals <18 years of age and those with
pregnancy, inflammatory diseases (such as asthma, sar-
coidosis, chronic obstructive pulmonary disease, inflam-
matory bowel disease and rheumatoid arthritis), malignant
diseases or Injury Severity Score (ISS) [31] ≥10 points in
non-cranial aspects. A total of 100 patients were included
in the study, and they were treated according to the Brain
Trauma Foundation guidelines [1].
The study was approved by the institutional review boards
of the six participating hospitals: Hospital Universitario
de Canarias (La Laguna, Santa Cruz de Tenerife, Spain),
Hospital Universitario Nuestra Señora de Candelaria (Santa
Cruz de Tenerife, Spain), Hospital General de La Palma
(La Palma, Spain), Hospital Clínico Universitario de Valencia
(Valencia, Spain), Hospital Insular (Las Palmas de Gran
Canaria, Spain) and Hospital Universitario Dr Negrín (Las
Palmas de Gran Canaria, Spain). Written informed consent
was obtained from the patients or their legal guardians.
Variables recorded
Blood samples were analyzed for glycemia, sodium, lactic
acid, creatinine, bilirubin, hemoglobin, platelets, fibrinogen,
international normalized ratio, activated partial thrombo-
plastin time (aPTT) and leukocytes. Brain lesions were
classified according to the Marshall computed tomography
(CT) criteria [32]. To estimate the clinical severity, we cal-
culated GCS, ISS and Acute Physiology and Chronic Health
Evaluation II (APACHE II) scores [33].
The Marshall CT lesion classification scheme [32] is
as follows:
 Class I or diffuse injury I: no visible pathology
 Class II or diffuse injury II: presence of cisterns with
midline shift 0 to 5 mm and no high- or mixed-
density lesion >25 ml
 Class III or diffuse injury III (swelling): cisterns
compressed or absent with midline shift 0 to 5 mm
and no high- or mixed-density lesion >25 ml
 Class IV or diffuse injury IV (shift): midline shift
>5 mm and no high- or mixed-density lesion >25 ml
 Class V or evacuated mass lesion: any lesion
evacuated
 Class VI or non-evacuated mass lesion: high- or
mixed-density lesion >25 ml not surgically evacuated
Endpoint
The endpoint of the study was 30-day mortality.
Substance P assay
A total of 5 ml of venous blood samples were collected on
day 1 of TBI (within the first 4 hours after TBI) through a
central venous catheter. The blood was added to serum
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30 minutes and then centrifuged at 1,000 × g for 15 mi-
nutes. Serum was removed and frozen at −80°C until SP
measurement.
SP assay was performed in the Genetics Unit of the
Instituto de Enfermedades Tropicales y Salud Pública de
Canarias of the University of La Laguna (Tenerife, Spain).
Serum SP levels were assayed by specific enzyme-linked
immunosorbent assay according to the manufacturer’s in-
structions (R&D Systems, Abingdon, UK). All samples
were assayed in duplicate at twofold dilutions in assay
buffer. Absorbance at 450 nm was measured using the
EnSpire multimode plate reader (PerkinElmer, Waltham,
MA, USA). The serum concentration of SP was expressed
in picograms per milliliter. The detection limit of this
assay was 25 pg/ml, and the intra- and interassay coeffi-
cients of variation were 9% and 15%, respectively. Samples
were all processed at the same time, at the end of the
recruitment process, by the same laboratory technician
using the same equipment and blinded to all clinical data.Statistical methods
Continuous variables are reported as medians and inter-
quartile ranges, and comparisons between groups were car-
ried out using the Wilcoxon-Mann-Whitney test. We used
the Kolmogorov-Smirnov test to compare the frequencies
distribution of our continuous variables with the theoretical
normal distribution. Because lack of normality was observed
in some variables included in the analysis, we used non-
parametric tests to compare groups. Categorical variables
are reported as frequencies and percentages, and compari-
sons between groups were carried out with the χ2 test.
Receiver operating characteristic curve analysis was
carried out to determine the area under the curve (AUC).
Kaplan-Meier analysis of 30-day survival was carried out
using serum SP levels higher or lower than 299 pg/ml as
the independent variable and survival at 30 days as the
dependent variable. Comparisons were performed using
the log-rank test. We used the Youden index (J) to select
the cutoff point of serum SP level for the prediction of
mortality at 30 days.
Multiple binomial logistic regression analyses were
carried out to determine the association between serum
SP levels and mortality at 30 days. In the first model, we
included CT findings with high risk of death (classes III, IV
and VI), APACHE II score and serum SP levels >299 pg/ml.
In the second model, we included age, GCS score and
serum SP levels >299 pg/ml. Odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated as measures
of the clinical impact of the predictor variables.
A P-value <0.05 was considered statistically signifi-
cant. Statistical analyses were performed with IBM SPSS
17.0 (IBM, Armonk, NY, USA), NCSS 2000 (Kaysville,UT, USA) and LogXact 4.1 (Cytel, Cambridge, MA,
USA) software.
Results
Comparisons of demographic and clinical severity data
between surviving and non-surviving patients with TBI are
shown in Table 1. We found a higher ratio of female
patients among non-survivors than among survivors (11
(40.7%) of 27 vs 12 (16.4%) of 73, respectively; P =0.02).
There were statistically significant differences in CT
findings between non-surviving and surviving patients
(P =0.002). We found a higher rate of CT findings with high
risk of death (classes III, IV and VI) in non-surviving than
in surviving patients (19 (70.4%) of 27 vs 26 (35.6%) of 73,
respectively; P =0.003). Non-surviving patients with TBI
had lower GCS scores (P <0.001), were older (P <0.001)
and had higher APACHE II scores (P <0.001) than survi-
vors. In addition, non-surviving patients had higher serum
SP levels than survivors (P =0.002).
The AUC for serum SP levels as a predictor of 30-day
mortality was 0.70 (95% CI, 0.60 to 0.79; P <0.001)
(Figure 1).
Survival analysis showed that patients with serum SP
levels >299 pg/ml had higher 30-day mortality than pa-
tients with lower levels (hazard ratio =3.7; 95% CI, 1.75
to 7.94; P <0.001) (Figure 2).
Multiple binomial logistic regression analysis showed
that serum SP levels >299 pg/ml were associated with
30-day mortality when we controlled for APACHE II
score and CT classification (OR =5.97; 95% CI, 1.432 to
24.851; P =0.01) and for GCS score and age (OR =5.71;
95% CI, 1.461 to 22.280; P =0.01) (Table 2).
We found no significant differences in serum SP levels
between female and male patients (222 (135 to 493) vs 319
(157 to 547) pg/ml, respectively; P =0.35). Similarly, no as-
sociation was observed between serum SP levels and intra-
cranial pressure (Spearman’s ρ = −0.10; P =0.26). On the
contrary, we found a negative association between serum
SP levels and GCS (Spearman’s ρ = −0.22; P =0.03).
Discussion
To our knowledge, this is the first study report of serum
SP levels in patients with severe TBI. Our data support an
important role of SP in TBI on the basis of our findings:
(1) Non-surviving TBI patients showed significantly
higher serum SP levels than survivors; (2) serum SP levels
were significantly associated with early mortality, suggest-
ing its potential as a biomarker; and (3) serum SP levels
were significantly associated with TBI severity. Taken to-
gether, all these findings suggest that serum SP levels may
be of great pathophysiological significance in patients with
TBI. We also found that other variables, such as age, GCS
score and CT findings, were associated with 30-day mor-
tality, which is in agreement with previous studies [34-38].
Table 1 Comparison of demographic and clinical severity data between traumatic brain injury survivors and
non-survivorsa
Non-survivors (n =27) Survivors (n =73) P-value
Glasgow Coma Scale score 3 (3 to 6) 7 (6 to 8) <0.001
APACHE II score 26 (25 to 32) 19 (17 to 23) <0.001
Age (yr) 66 (45 to 76) 47 (32 to 67) <0.001
Substance P (pg/ml) 420 (310 to 815) 250 (99 to 496) 0.002
CT findings 0.002
Class I 0 0
Class II 3 (11.1) 21 (28.8)
Class III 5 (18.5) 13 (17.8)
Class IV 6 (22.2) 10 (13.7)
Class V 5 (18.5) 26 (35.6)
Class VI 8 (29.6) 3 (4.1)
Female sex 11 (40.7) 12 (16.4) 0.02
Temperature (°C) 36.0 (35.0 to 37.0) 37.0 (35.6 to 37.3) 0.12
Sodium (mEq/L) 141 (135 to 149) 139 (138 to 142) 0.19
Platelets (*103/mm3) 215 (139 to 264) 182 (143 to 252) 0.48
PaO2 (mmHg) 141 (104 to 186) 151 (116 to 217) 0.34
PaO2/FiO2 ratio 190 (154 to 316) 336 (242 to 407) 0.11
Leukocytes (*103/mm3) 18.3 (10.7 to 23.9) 14.7 (10.2 to 19.3) 0.46
Lactic acid (mmol/L) 1.90 (1.15 to 4.55) 1.70 (1.23 to 2.50) 0.16
Intracranial pressure (mmHg) 20 (12 to 30) 15 (14 to 20) 0.27
International normalized ratio 1.22 (1.01 to 1.67) 1.03 (0.92 to 1.15) 0.15
Injury Severity Score 25 (25 to 27) 25 (25 to 32) 0.24
Hemoglobin (g/dl) 11.1 (9.4 to 12.3) 11.4 (10.4 to 13.0) 0.87
Glycemia (g/dl) 161 (142 to 189) 139 (120 to 163) 0.08
Fibrinogen (mg/dl) 376 (246 to 560) 350 (282 to 444) 0.32
Creatinine (mg/dl) 0.95 (0.70 to 1.10) 0.80 (0.70 to 0.90) 0.44
Cerebral perfusion pressure (mmHg) 60 (54 to 69) 68 (57 to 70) 0.46
Bilirubin (mg/dl) 0.75 (0.53 to 1.05) 0.50 (0.40 to 0.87) 0.045
aPTT (seconds) 26 (25 to 31) 28 (25 to 32) 0.86
aAPACHE II, Acute Physiology and Chronic Health Evaluation II; aPTT, Activated partial thromboplastin time; CT, Computed tomography; PaO2, Partial pressure of
arterial oxygen; PaO2/FiO2 ratio, Ratio of partial pressure of arterial oxygen to fraction of inspired oxygen. Data shown are number (percentage) or median (25th to
75th percentiles).
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adult neural progenitor cells [39]; increases axonal growth
from the dorsal horn [40]; and promotes neurite outgrowth
[41]. In spite of this beneficial action on neurogenesis, sev-
eral studies carried out in animal models support a deleteri-
ous role of SP in TBI. In rats, SP release after severe diffuse
TBI increased vascular permeability and edema formation,
both of which were attenuated after administration of a
NK1R antagonist [10,11]. SP can promote proliferation
[42], chemotaxis [43] and activation of microglia [18,25],
and the subsequent release of proinflammatory cytokines
by activated cells may impair neurogenesis and motor
outcome [44-46]. In fact, treatment of rats with a NK1R
antagonist after TBI improved functional outcome [42]. Inaddition, proinflammatory mediators can be released by
other brain cells expressing NK1R in response to SP, such
as astrocytes and neuronal cells, contributing to an increase
in the inflammatory response [20-23]. Finally, capsaicin, a
substance that induces SP depletion from sensory nerves,
administered to rats before TBI attenuated blood brain–
barrier opening, edema formation and the development of
both motor and cognitive deficits [6]. These results ob-
tained in small animal models have been reproduced using
an ovine model of TBI [47]. In this model, administration
of a NK1R antagonist decreased edema formation and
caused a profound reduction in posttraumatic intracranial
pressure. In humans, a recent study carried out with archival
postmortem material found increased SP immunoreactivity
Figure 1 Receiver operating characteristic curve analysis of serum
substance P levels to predict 30-day mortality. AUC, Area under the curve;
CI Confidence interval.
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compared with patients with no neuropathological abnor-
mality [7].
Taking into account all these data, we proposed that brain
injury in humans induces SP release from sensory neurons,
which trigger a cascade of events that results in activation
of NK1R in cerebral blood vessels, leading to increasedFigure 2 Survival curves at 30 days using serum substance P levels highervascular permeability and edema formation. In addition, ac-
tivation of neurons, astrocytes and microglia by SP leads to
inhibition of neurogenesis and chemotaxis of inflammatory
and immune cells to the site of injury. Inflammatory cells
may use SP as a paracrine or autocrine signaling mechanism
to propagate inflammation beyond the limited topographic
spread of the sensory neurons [48]. The concentration of
neuroimmune SP increases in the brain, leaking into the
bloodstream, where it can be quantitated in serum or
plasma samples. This measurement would allow identifica-
tion of those patients with an exacerbated inflammatory
response. This is particularly interesting because NK1R
antagonists have been approved for commercial use to treat
different pathologies [49-51], and they could be an attractive
therapeutic option for these patients [52].
The observed association of SP with higher mortality
may be due to malignant and inflammatory conditions
that are known to increase SP levels [53-55]. However,
patients with diseases such as asthma, sarcoidosis, chronic
obstructive pulmonary disease, inflammatory bowel dis-
ease, rheumatoid arthritis or malignant diseases were not
included in the present study. Even so, we cannot discount
the possibility that other conditions may influence SP
levels. Elevated serum SP levels could reflect greater injury
severity and hence higher mortality. However, multiple
logistic regression analysis showed that serum SP levels
were associated with mortality after we controlled for
GCS and APACHE II scores and age.
Previous studies have shown that serum SP levels vary
considerably over time after TBI [10]. Thus, as soon asor lower than 299 pg/ml as the cutoff. CI, Confidence interval.
Table 2 Multiple binomial logistic regression analysis to predict 30-day mortalitya
Odds ratio 95% confidence interval P-value
First model
APACHE II score 1.39 1.188 to 1.622 <0.001
CT with high risk of death (classes III, IV and VI) 4.61 1.067 to 19.967 0.04
Serum substance P levels >299 pg/ml 6.64 1.507 to 29.238 0.01
Sex female 2.66 0.591 to 11.966 0.20
Second model
Age 1.08 1.029 to 1.122 <0.001
GCS score 0.56 0.396 to 0.776 <0.001
Serum substance P levels >299 pg/ml 7.28 1.650 to 32.086 0.01
Female sex 3.92 0.765 to 20.118 0.10
aAPACHE II, Acute Physiology and Chronic Health Evaluation; CT, Computed tomography; GCS, Glasgow Coma Scale.
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levels was observed in mice, but these levels decreased by
5 hours, presumably due to rapid proteolysis by non-specific
serum proteases [10]. In our study, all samples were col-
lected within 4 hours after TBI, although the exact interval
between the injury, hospital admission and blood collection
were not recorded. In addition, we did not analyze serum
SP levels during follow-up. Therefore, information regarding
sample collection period and patient monitoring would
be desirable in future studies to determine the role of
SP in TBI.
Although the mortality rate in our series (27%) is similar
to that reported in other studies [56,57], it should be noted
that the mortality rate may be different in series with a dif-
ferent case mix (that is, with regard to GCS, APACHE II,
age and CT findings). Moreover, owing to the low number
of events (deaths), we included only three variables in the
multiple logistic regression analysis to avoid a final model of
order slightly higher than required due to an overfitting ef-
fect [58]. In addition, in the multiple regression analysis, we
included those variables that showed statistically significant
differences in the bivariate analysis when survivors and non-
survivors were compared. We also used two models to avoid
the effects of collinearity. Thus, we constructed two multiple
binomial logistic regression models with only three predictor
variables in each model, including serum SP levels in both
models. One model controlled for CT findings and APA-
CHE II score, and the other controlled for age and GCS
score. We found that serum SP levels were associated with
mortality in both models, which strongly supports the role
of SP in TBI. However, larger series of patients and the
inclusion of more variables in a single multiple logistic
regression analysis are needed to confirm our findings.
Conclusions
The most relevant findings of our study, which is the first
to include data on serum SP levels in patients with severe
TBI to our knowledge, are that non-surviving TBI patientsshowed higher serum SP levels than survivors, that serum
SP levels were associated with severity and mortality, and
that serum SP levels could be used as a biomarker to pre-
dict mortality in patients with severe TBI. These results
open the possibility that NK1R antagonists may be useful
for the treatment of severe TBI.Key messages
 Serum substance P levels are associated with TBI
severity.
 Non-surviving TBI patients showed higher serum
substance P levels than survivors.
 Serum substance P levels are associated with TBI
mortality.
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